Prospects for gene therapy in Parkinson's disease

Movement Disorders

Volumn 11, Issue 5, 1996, Pages 469-488

  Freese, Andrew ^a,b,e   Stern, Matthew ^b   Kaplitt, Michael G ^c   O'Connor, William M ^b   Abbey, Maureen V ^b   O'Connor, Michael J ^a,b   During, Matthew J ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b GRADUATE HOSPITAL   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Gene therapy; Parkinson's disease; Transgenes; Transplant; Viral vector

Indexed keywords

DOPAMINE; ENZYME; NEUROTROPHIC FACTOR;

DOPAMINE METABOLISM; EXPRESSION VECTOR; GENE THERAPY; GENE TRANSFER; HUMAN; NERVE CELL DEGENERATION; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; REGENERATION; REVIEW; TRANSGENE;

EID: 0029838423     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870110502     Document Type: Review

References (112)

1. Freese A, Neve R, Geller AI. HSV-1 vector mediated neuronal gene delivery: strategies for neuroscience and neurology. Biochem Pharm 1990;40:2189-2199.
2. Geller AI, Freese A. Transfection of cultured central nervous system neurons with a defective HSV-1 vector which expresses β-galactosidase. Proc Natl Acad Sci USA 1990; 87:1149-1153.
3. Davidson BL, Allen ED, Kozarsky KF, Wilson JM, Roessler BJ. A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. Nature Genet 1993;3:219-223.
4. Kaplitt MG, Leone P, Samulski RJ, et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nature Genet 1994;8:148-154.
5. Spaete RR, Frenkel N. The herpes simplex virus amplicon: a new eucaryotic defective virus cloning-amplifying vector. Cell 1982;30:295-304.
6. Palella TD, Hidaka Y, Silverman LJ, Levine M, Glorioso J, Kelley WN. Expression of human HPRT mRNA in brains of mice infected with a recombinant herpes simplex virus-1 vector. Gene 1989;80:137-144.
7. Baringer JR, Sworeland P. Recovery of herpes-simplex virus from human trigeminal ganglions. N Engl J Med 1973; 228:9593-9596.
8. Cook ML, Bastone UB, Stevens JG. Evidence that neurons harbor latent herpes simplex virus. Infect Immun 1974;9: 946-951.
9. Geller AI, Breakfield XO. A defective HSV-1 vector expresses Escherichia coli β-galactosidase in cultured peripheral neurons. Science 1988;241:1667-1669.
10. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991;252:854-856.
11. Geller AI, During MJ, Neve RL. Molecular analysis of neuronal physiology by gene transfer into neurons with herpes simplex virus vectors. Trends Neurosci 1991;14:428-432.
12. Chiocca EA, Choi BB, Cai W, DeLuca NA, et al. Transfer and expression of the Lac Z gene in rat brain neurons mediated by herpes simplex virus insertion mutants. New Biol 1990;2:739-746.
13. Mellerick DM, Fraser NW. Physical state of the latent herpes simplex virus genome in a mouse model system: evidence suggesting an episomal state. Virology 1987;158: 265-275.
14. Markert JM, Coen DM, Malick A, Mineta T, Martuza RL. Expanded spectrum of viral therapy in the treatment of nervous system tumors. J Neurosurg 1992;77:590-594.
15. Kaplitt MG, Tjuvajev JG, Leib DA, et al. Mutant herpes simplex virus induced regression of tumors in immunocompetent rats. J Neurooncol 1994;19:137-147.
16. Dobson AT, Margolis TP, Sedarati F, Stevens JG, Feldman LT. A latent, nonpathogenic HSV-1-derived vector stably expresses β-galactosidase in mouse neurons. Neuron 1990; 5:353-360.
17. Andersen JK, Garber DA, Meaney CA, Breakefield XO. Gene transfer into mammalian central nervous system using herpes virus vectors: extended expression of bacterial lacZ in neurons using the neuron-specific enolase promoter. Hum Gene Ther 1992;3:487-499.
18. Randazzo BP, Freese A, Kesari S, Brown SM, Maclean AR, Fraser NW. Treatment of cerebral metastases with herpes simplex virus one mutant 1716: culture and animal studies. Proc Am Assoc Neurol Surg 1995;63:1395.
19. Glorioso JC, Goins WF, Meaney CA, Fink DJ, DeLuca NA. Gene transfer to brain using herpes simplex virus vectors. Ann Neurol 1994;35:28-34.
20. Vlazny DA, Frenkel N. Replication of herpes simplex virus DNA: localization of replication recognition signals within defective virus genomes. Proc Natl Acad Sci USA 1981; 78:742-746.
21. Vlazny DA, Kwong A, Frenkel N. Site-specific cleavage/ packaging of herpes simplex virus DNA and the selective maturation of nucleocapsids containing full-length viral DNA. Proc Natl Acad Sci USA 1979;79:1423-1427.
22. Freese A, Geller AI. Infection of cultured striatal neurons with a defective HSV-1 vector: implications for gene therapy. Nucl Acids Res 1991;19:7219-7223.
23. Geller AI, During MJ, Haycock JW, Freese A, Neve R. Long term increases in neurotransmitter release from neuronal cells expressing a constitutively active adenylate cyclase from a herpes simplex virus type 1 vector. Proc Natl Acad Sci USA 1993;90:7603-7607.
24. Geller AI, During MJ, Oh YJ, Freese A, O'Malley K. A HSV-1 vector expressing tyrosine hydroxylase causes production and release of L-dopa and dopamine from cultured striatal neurons. J Neurochem 1995;64:487-496.
25. Kwong D, Frenkel N. The herpes simplex virus virion host shutoff function. J Virol 1989;63:4834-4839.
26. During MJ, Naegele JR, O'Malley KL, Geller AI. Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science 1994;266: 1399-1403.
27. O'Malley K, Geller AI. Gene therapy in neurology: potential application to Parkinson's Disease. In: Vecsei L, Freese A, Swartz KJ, Beal MF, eds. Neurological disorders: novel experimental and therapeutic strategies. West Sussex: Ellis Horwood Limited, 1992:223-248.
28. Kaplitt MG, Pfaus JG, Kleopoulos SP, Hanlon BA, Rabkin SD, Pfaff DW. Expression of a functional foreign gene in adult mammalian brain following in vivo transfer via a herpes simplex virus type 1 defective viral vector. Mol Cell Neurosci 1991;2:320-330.
29. Federoff HJ, Geschwind MD, Geller AI, Kessler JA. Expression of nerve growth factor in vivo from a defective herpes simplex virus 1 vector prevents effects of axotomy on sympathetic ganglia. Proc Natl Acad Sci USA 1992;89: 1636-1640.
30. Ho DY, Mocarski ES, Sapolsky RM. Altering central nervous system physiology with a defective herpes simplex virus vector expressing the glucose transporter gene. Proc Natl Acad Sci USA 1993;90:3655-3659.
31. Kaplitt MG, Kwong AD, Kleopoulos SP, Mobbs CV, Rabkin SD, Pfaff DW. Preproenkephalin promoter yields region-specific and long-term expression in adult brain after direct in vivo gene transfer via a defective herpes simplex viral vector. Proc Natl Acad Sci USA 1994;19:8979-8983.
32. Yurek DM, Sladek JR Jr. Dopamine cell replacement: Parkinson's disease. Annu Rev Neurosci 1990;13:415-440.
33. O'Malley KL, Anhalt MJ, Martin BM, Kelsoe JR, Winfield SL, Ginns EI. Isolation and characterization of the human tyrosine hydroxylase gene: identification of 5′ alternative splice sites responsible for multiple mRNAs. Biochemistry 1987;26:6910-6914.
34. Kobayashi K, Kiuchi K, Ishii A, et al. Expression of four types of human tyrosine hydroxylase in COS cells. FEBS Lett 1988;238:431-434.
35. Cooper JR, Bloom FE, Roth RH. The biochemical basis of neuropharmacology. New York: Oxford University Press, 1986.
36. Sabel BA, Dominiak P, Hauser W, During MJ, Freese A. Levodopa delivery from a controlled release polymer matrix: delivery of more than 600 days and 225 days of elevated plasma levels after subcutaneous implantation in rats. J Pharmacol Exp Ther 1990;255:914-922.
37. Birkmayer W. Experimentalle ergebnise uber die Kombinationsbehandlung des Parkinson-syndroms mit L-dopa und einem decarboxylasehemmer. Wiener Klin Wochenschr 1969;81:677-679.
38. Fahn S. "On-off" phenomenon with levodopa therapy in parkinsonism. Neurol 1974;24:431-441.
39. Freese A, Sabel BA, Saltzman WM, During MJ, Langer R. Controlled release of dopamine from a polymeric brain implant: in vitro characterization. Exp Neurol 1989;103:234-238.
40. Mouradian MM, Juncos JL, Fabbrini G, Chase TN. Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies. Ann Neurol 1987;22:475-479.
41. Barbeau A. The clinical physiology of side effects in long term L-dopa therapy. Adv Neurol 1974;5:347-356.
42. Chase TN, Juncos J, Serrati C, Fabbrini G, Bruno G. Fluctuations in response to chronic levodopa therapy: pathogenetic and therapeutic considerations. In: Yahr MD, Bergmann KJ, eds. Advances in neurology: Parkinson's disease. New York: Raven Press, 1986:477-480.
43. Hardie RJ, Lees AJ, Stern GM. On-off fluctuations in Parkinson's disease: a clinical and neuropharmacologic study. Brain 1984;107:487-506.
44. Bittkau S, Przuntek H. Chronic sc lisuride in Parkinson's disease - motor performance and avoidance of psychiatric side effects. J Neural Transm Suppl 1988;27:35-54.
45. During MJ, Freese A, Sabel BA, et al. Controlled release of dopamine from a polymeric brain implant: in vivo characterization. Ann Neurol 1989;25:351-356.
46. Sabel BA, Dominiak P, Hauser W, During MJ, Freese A. Extended levodopa release from a subcutaneously implanted polymer matrix in rats. Ann Neurol 1990;28:714-717.
47. Cedarbaum JH, Breck L, Kuff H, McDowell FH. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease. Neurology 1987;37:233-241.
48. Horrelou P, Brundin P, Kalen P, Mallet J, Bjorklund A. In vivo release of dopa and dopamine from genetically engineered cells grafted to the denervated rat striatum. Neuron 1990;5:393-402.
49. Hefti F, Melamed E, Wurtman RJ. The decarboxylation of dopa in the Parkinsonian brain: m vivo studies on an animal model. J Neural Transm 1980;16:95-101.
50. Melamed E, Hefti F, Wurtman RJ. Non-aminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Ann Neurol 1980;8:558-563.
51. Freese A, During MJ, O'Malley K, Geller AI. Expression of tyrosine hydroxylase in striatal cells with a HSV-1 vector causes stable production and regulated release of dopa and dopamine: potential gene therapy for Parkinson's disease. Abstr Soc Neurosci 1991;17:424.15.
52. Freese A, DiFiglia M, Beal MF, Martin JB. Characterization and mechanism of glutamate toxicity in primary striatal cultures. Brain Res 1990;521:254-264.
53. Koroshetz WJ, Freese A, DiFiglia M. Correlation between excitatory amino acid induced current responses and excitotoxicity in striatal cultures. Brain Res 1990;521:265-272.
54. Freese A, Finklestein S, DiFiglia M. Basic fibroblast growth faclor protects striatal neurons in vitro from NMDA receptor mediated excitotoxicity. Brain Res 1992;575:351-355.
55. Hefti F, Melamed BJ, Sahakian BJ, Wurtman RJ. Circling behavior in rats with partial, unilateral nigrostriatal lesions: effects of amphetamine, apomorphine and DOPA. Pharmacol Biochem Behav 1980;12:185-188.
56. During MJ, Freese A, Deutch AY, et al. Biochemical and behavioral recovery in a rodent model of Parkinson's disease following stereotactic implantation of dopamine-containing liposomes. Exp Neurol 1992;115:193-199.
57. During MJ, Geller AI, Freese A, Neve R. Neuronal expression of parvalbumin and calcium/calmodulin dependent protein kinase II from HSV-1 vectors. Abstr Soc Neurosci 1990;16:216.4.
58. During MJ. Genetic manipulation of signal transduction pathways in the adult mammalian brain. Abstr Soc Neurosci 1992;18:453.3.
59. Leone P, Geller AI, During MJ. A HSV-1 vector expressing unregulated PKC from the TH promoter improves spatial navigation performance following intrahippocampal injection in young adult rats. J Neurochem 1993;61:135-137.
60. Song S, Leone P, Wang Y, et al. Rotational behavior in adult rats is induced by selective activation of the protein kinase C pathway in substantia nigra pars compacta neurons with a HSV-1 vector. Abstr Soc Neurosci 1993;19: 328.2.
61. Johnson PA, Miyanohara A, Levine F, Cahill T, Friedmann T. Cytotoxicity of a replication-defective mutant of herpes simplex virus type 1. J Virol 1992;66:2952-2965.
62. Huang Q, Vonsattel J-P, Schaffer PA, Martuza RL, Breakefield XO, DiFiglia M. Introduction of a foreign gene (Escherichia coli lacZ) into rat neostriatal neurons using herpes simplex virus mutants: a light and electron microscopic study. Exp Neurol 1992;115:303-316.
63. Jacoby DR, Breakefield XO, Latchman DS. Construction of an HSV-1 amplicon with an inducible Oct-2 operon to modulate cytopathic effect. Proceedings of the International Conference on Gene Therapy for CNS Disorders 1995;1.31.
64. Geller A, Song S, Lim F, et al. A helper virus-free packaging system for HSV-1 plasmid vectors that supports efficient gene transfer in the rat brain. Abstr Soc Neurosci 1995;21:330.1.
65. Freese A, Kaplitt MG, O'Connor MJ, O'Connor WM, During MJ. Gene transfer into human hippocampal slices with an adeno-associated virus vector. Abstr Soc Neurosci 1994; 20:592.15.
66. Samulski RJ, Chang L-S, Shenk T. Helper-free stocks of adeno-associated viruses: normal integration does not require viral gene expression. J Virol 1989;63:3822-3828.
67. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol 1992;158:97-129.
68. Lippman C, Welsh F, Kaplitt MG, O'Connor WM, During MJ, O'Connor MJ, Freese A. Transfer of the human heal shock protein-72 gene into cultured cells using an adeno-associated virus vector. Proceedings of the International Conference on Gene Therapy for CNS Disorders 1995;4.11.
69. Freese A, O'Connor MJ, Kaplitt MG, O'Connor WM, During MJ. Adeno-associated virus vector mediated gene transfer into human hippocampal slices. Epilepsia 1994;35: 62.
70. Redmond DE Jr, O'Malley KL, Kaplitt MG, et al. AAV vectored gene therapy in primate parkinsons model. Abstr Soc Neurosci 1995;21:224.22.
71. Redmond DE, O'Malley KL, Kaplitt MG, et al. AAV vector gene therapy in a primate Parkinson's model. Proceedings of the International Conference on Gene Therapy for CNS Disorders 1995;3.10.
72. During MJ, Kaplitt MG, Leone P, et al. AAV-mediated transfer of tyrosine hydroxylase and aromatic amino acid decarboxylase into the primate brain: a direct gene therapy approach to Parkinson's disease. Abstr Soc Neurosci 1994; 20:602.10.
73. During MJ, Choi-Lundberg D, Leone P, et al. Neuroprotection and neuroregeneration in rodent and primate parkinsonian models using an AAV vector expressing GDNF. Abstr Soc Neurosci 1995;21:225.9.
74. Lin L-FH, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993;260:1130-1132.
75. Lindsay RM. Neuron saving schemes. Nature 1995;273: 289-290.
76. Tomac A, Lindqvist E, Lin L-FH, et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995;373:335-339.
77. Yan Q, Matheson C, Lopez OT. In vivo neurotrophic effects of GDNF on neonatal and adult facial motor neurons. Nature 1995;373:341-344.
78. Beck K, Valverde J, Alexi T, et al. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 1995;373: 339-341.
79. Oppenheim RW, Houenou LJ, Johnson JE, et al. Developing motor neurons rescued from programmed and axotomy-induced cell death by GDNF. Nature 1995;373:344-346.
80. Kang UJ, Bencsics C, Cahill AL, Hatakeyama K, Milstein S. Regulation of L-dopa production by 5,6,7,8 tetrahydro-L-biopterin in genetically modified cells. Proceedings of the International Conference on Gene Therapy for CNS Disorders 1995:3.11.
81. Le Gal La Salle G, Robert JJ, et al. An adenovirus vector for gene transfer into neurons and glia in the brain. Science 1993;259:988-990.
82. Akli S, Caillaud C, Vigne E, et al. Transfer of a foreign gene into the brain using adenovirus vectors. Nature Genet 1993;3:221-228.
83. Bajocchi G, Feldman SH, Crystal RG, Mastrangeli A. Direct in vivo gene transfer to ependymal cells in the central nervous system using recombinant adenovirus vectors. Nature Genet 1993;3:229-234.
84. Horrelou P, Vigne E, Castel M-N, et al. Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease. Neuroreport 1994;6:49-53.
85. Lin O, Choi-Lundberg DL, Ravenell J, et al. Adenoviral (Ad)-mediated gene transfer of GDNF and β-galactosidase (lac Z) to the rat nigrostriatal system in vitro and in vivo. Abstr Soc Neurosci 1995;21:224.12.
86. Goodman JC, Trask TW, Chen S-H, et al. Toxicity of adenoviral mediated brain tumor gene therapy in primates. Proceedings of the International Conference on Gene Therapy for CNS Disorders 1995:2.10.
87. Neuwelt EA, Barranger JA, Brady RO. Delivery of hexosaminidase A to the cerebrum after osmotic modification of the blood-brain barrier. Proc Natl Acad Sci USA 1981; 78:5838-5841.
88. 35S-herpes virus across an osmotically modified blood-brain barrier. J Neurosurg 1991;74:475-479.
89. Doran SE, Ren XO, Betz AL, et al. Gene expression from recombinant viral vectors in the central nervous system after blood-brain barrier disruption. Neurosurgery 1995;36: 965-970.
90. Neuwelt EA, Weissleder R, Milaver G, et al. Delivery of virus-sized iron oxide particles to rodent CNS neurons. Neurosurgery 1994;34:777-784.
91. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994;90: 6165-6169.
92. Rosenberg MB, Friedmann T, Robertson RL, et al. Grafting genetically modified cells to the damaged brain: restorating effects of NGF expression. Science 1988;242: 1575-1578.
93. Ray J, Gage FH. Gene transfer into established and primary fibroblast cell lines: comparison of transfection methods and promoters. Biotechniques 1992;13:598-603.
94. Palmer TD, Rosman GJ, Osborne WRA, Miller AD. Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc Natl Acad Sci USA 1991;88:1330-1334.
95. Scharfmann R, Axelrod JH, Verma IM. Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants. Proc Natl Acad Sci USA 1991;88:4626-4630.
96. Mallet J, Horrelou P, LeGal LaSalle G, et al. Gene therapy approaches to neurodegenerative diseases. Proceedings of the International Conference on Gene Therapy for CNS Disorders 1995:3.01.
97. Horrelou P, Sabate O, Buc-Caron M-H, et al. In vivo and ex vivo gene therapy in a rat model of Parkinson's disease. Proceedings of the International Conference on Gene Therapy for CNS Disorders 1995:3.15.
98. Wolff JA, Fisher LJ, Xu L, et al. Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease. Proc Natl Acad Sci USA 1989;86:9011-9014.
99. Kawaja MD, Gage FH. Morphological and neurochemical features of cultured primary skin fibroblasts of Fischer 344 rats following striatal implantation. J Comp Neurol 1992; 317:102-116.
100. Uchida K, Ishii A, Kaneda N, Toya S, Nagatsu T, Kohsaka S. Tetrahydrobiopterin-dependent production of L-dopa in NRK fibroblasts transfected with tyrosine hydroxylase cDNA: future use for intracerebral grafting. Neurosci Lett 1990;109:282-286.
101. Uchida K, Takamatsu K, Kaneda N, et al. Synthesis of L-3,4-dihydroxyphenylalanine by tyrosine hydroxylase cDNA-transfected C6 cells: application for intracerebral grafting. J Neurochem 1989;53:728-732.
102. Horellou P, Marlier L, Privat A, Mallet J. Behavioral effect of engineered cells that synthesize L-dopa or dopamine after grafting into the rat neostriatum. Eur J Neurosci 1990; 2:116-119.
103. Horellou P, Brundin P, Kalen P, Mallet J, Bjorklund A. In vivo release of dopa and dopamine from genetically engineered cells grafted to the denervated rat striatum. Neuron 1990;5:393-402.
104. Fisher LJ, Jinnah HA, Kale LC, Higgins GA, Gage FH. Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-dopa. Neuron 1991;6:371-380.
105. Kang UJ, Fisher LJ, Joh TH, O'Malley KL, Gage FH. Regulation of dopamine production by genetically modified fibroblasts. J Neurosci 1993;13:5203-5211.
106. Jiao S, Wolff JA. Long-term survival of autologous muscle grafts in rat brain. Neurosci Lett 1992;137:207-210.
107. Jiao S, Gurevich V, Wolff JA. Long-term correction of rat model of Parkinson's disease by gene therapy. Nature 1993;362:450-453.
108. Jiao S, Schultz E, Wolff JA. Intracerebral transplants of primary muscle cells: a potential "platform" for transgene expression in the brain. Brain Res 1992;575:143-147.
109. Morassutti DJ, Atasoy E, Staines WA, McBurney MW. Characterization of murine P19 EC-derived neurons expressing foreign rat TH cDNA-in vitro and in vivo. Proceedings of the International Conference on Gene Therapy for CNS Disorders 1995:3.12.
110. Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O. Implanted fibroblasts genetically, engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridium toxicity to dopamine neurons in the rat. Proc Natl Acad Sci USA 1994;91:5104-5108.
111. Hofer MM, Barde Y-A. Brain-derived neurotrophic factor prevents neuronal death in vivo. Nature 1988;331:261-262.
112. Lysaght MJ, Frydel B, Gentile F, Emerich D, Winn S. Recent progress in immunoisolated cell therapy. J Cell Biochem 1994;56:196-203.